

Josã© Manuel Afonso Moreira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7154421/publications.pdf>

Version: 2024-02-01

70
papers

2,739
citations

147566

31
h-index

182168

51
g-index

71
all docs

71
docs citations

71
times ranked

6043
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 1290.	1.7	17
2	Functional Proteomic Profiling of Triple-Negative Breast Cancer. <i>Cells</i> , 2021, 10, 2768.	1.8	10
3	HLA Class II Histocompatibility Antigen β Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer. <i>Cancers</i> , 2021, 13, 6179.	1.7	7
4	Metallopeptidase inhibitor 1 (TIMP1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2646-2662.	2.1	11
5	Allosteric regulation of AMP-activated protein kinase by adenylate nucleotides and small-molecule drugs. <i>Biochemical Society Transactions</i> , 2019, 47, 733-741.	1.6	19
6	Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6082.	1.8	7
7	Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion. <i>Oncogene</i> , 2019, 38, 3170-3184.	2.6	17
8	Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1. <i>Oncogenesis</i> , 2018, 7, 14.	2.1	20
9	The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms. <i>International Journal of Cancer</i> , 2018, 142, 2529-2542.	2.3	63
10	Predictive value of combined analysis of pro-NG2 and ERG in localized prostate cancer. <i>Apmis</i> , 2018, 126, 804-813.	0.9	12
11	Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening. <i>Stem Cells</i> , 2017, 35, 1898-1912.	1.4	13
12	Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. <i>PLoS ONE</i> , 2017, 12, e0188827.	1.1	9
13	Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. <i>BMC Cancer</i> , 2016, 16, 34.	1.1	35
14	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. <i>BMC Genomics</i> , 2016, 17, 442.	1.2	25
15	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59441-59457.	0.8	7
16	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. <i>International Journal of Cancer</i> , 2015, 137, 2470-2477.	2.3	8
17	High level PHGDH expression in breast is predominantly associated with keratin β -positive cell lineage independently of malignancy. <i>Molecular Oncology</i> , 2015, 9, 1636-1654.	2.1	34
18	Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. <i>Tumor Biology</i> , 2015, 36, 4327-4338.	0.8	36

#	ARTICLE	IF	CITATIONS
19	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. <i>Molecular Oncology</i> , 2015, 9, 1169-1185.	2.1	91
20	Topoisomerase- α 1 gene copy aberrations are frequent in patients with breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 2000-2006.	2.3	14
21	Drug transporters in breast cancer: response to anthracyclines and taxanes. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1075-1092.	1.1	6
22	Comparative Analysis of Evolutionarily Conserved Motifs of Epidermal Growth Factor Receptor 2 (HER2) Predicts Novel Potential Therapeutic Epitopes. <i>PLoS ONE</i> , 2014, 9, e106448.	1.1	3
23	FABP7 and HMGS2 Are Novel Protein Markers for Apocrine Differentiation Categorizing Apocrine Carcinoma of the Breast. <i>PLoS ONE</i> , 2014, 9, e112024.	1.1	23
24	CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. <i>Journal of Cell Biology</i> , 2014, 204, 713-727.	2.3	64
25	Looking back, to go forward. <i>Molecular Oncology</i> , 2014, 8, 445-446.	2.1	2
26	Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130098.	1.8	91
27	Proteomic analysis of tissue samples in translational breast cancer research. <i>Expert Review of Proteomics</i> , 2014, 11, 285-302.	1.3	12
28	Purification and characterization of bioactive his6-tagged recombinant human tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expressed at high yields in mammalian cells. <i>Protein Expression and Purification</i> , 2014, 101, 157-164.	0.6	8
29	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3590-3590.	0.8	0
30	Proximity probing assays for simultaneous visualization of protein complexes <i>in situ</i> . <i>Expert Review of Proteomics</i> , 2013, 10, 219-221.	1.3	4
31	Tumor interstitial fluid "A treasure trove of cancer biomarkers. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2259-2270.	1.1	64
32	TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells. <i>Journal of Proteome Research</i> , 2013, 12, 4136-4151.	1.8	36
33	Contribution of Na ⁺ , HCO ₃ ⁻ cotransport to cellular pH control in human breast cancer: A role for the breast cancer susceptibility locus NBCn1 (SLC4A7). <i>International Journal of Cancer</i> , 2013, 132, 1288-1299.	2.3	104
34	Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 381-394.	2.5	40
35	Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development. <i>Frontiers in Oncology</i> , 2013, 3, 313.	1.3	42
36	ErbB2-Driven Breast Cancer Cell Invasion Depends on a Complex Signaling Network Activating Myeloid Zinc Finger-1-Dependent Cathepsin B Expression. <i>Molecular Cell</i> , 2012, 45, 764-776.	4.5	112

#	ARTICLE	IF	CITATIONS
37	Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer. PLoS ONE, 2012, 7, e45967.	1.1	8
38	Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer, 2010, 10, 444.	1.1	77
39	Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer. Molecular and Cellular Proteomics, 2010, 9, 161-177.	2.5	45
40	Up-regulated Proteins in the Fluid Bathing the Tumour Cell Microenvironment as Potential Serological Markers for Early Detection of Cancer of the Breast. Molecular Oncology, 2010, 4, 65-89.	2.1	88
41	Tissue proteomics of the human mammary gland: Towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Molecular Oncology, 2010, 4, 539-561.	2.1	24
42	Challenges and Opportunities in Oncoproteomics. Molecular Oncology, 2010, 4, 459-460.	2.1	2
43	Proteomic Profiling of Mammary Carcinomas Identifies C7orf24, a γ -Glutamyl Cyclotransferase, as a Potential Cancer Biomarker. Journal of Proteome Research, 2010, 9, 3941-3953.	1.8	55
44	Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Molecular Oncology, 2009, 3, 220-237.	2.1	43
45	Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics - Clinical Applications, 2008, 2, 974-988.	0.8	11
46	A single lysis solution for the analysis of tissue samples by different proteomic technologies. Molecular Oncology, 2008, 2, 368-379.	2.1	31
47	A Combined Proteome and Ultrastructural Localization Analysis of 14-3-3 Proteins in Transformed Human Amnion (AMA) Cells. Molecular and Cellular Proteomics, 2008, 7, 1225-1240.	2.5	23
48	15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma. Molecular and Cellular Proteomics, 2008, 7, 1795-1809.	2.5	31
49	Clinical Proteomics. Molecular and Cellular Proteomics, 2008, 7, 1779-1779.	2.5	6
50	Characterization of Activated Stroma Cells and Externalized Proteins in 3D Human Breast Cancer Model. Apmis, 2008, 116, 421-421.	0.9	0
51	Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Molecular Oncology, 2007, 1, 97-119.	2.1	32
52	Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Molecular Oncology, 2007, 1, 321-349.	2.1	24
53	Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia. FEBS Letters, 2006, 580, 2935-2944.	1.3	48
54	Proteomic analysis of urinary fibrinogen degradation products in patients with urothelial carcinomas. Clinical Proteomics, 2006, 2, 45-65.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Apocrine Cysts of the Breast. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 462-483.	2.5	33
56	Down-regulation of the Tumor Suppressor Protein 14-3-3 β Is a Sporadic Event in Cancer of the Breast. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 555-569.	2.5	66
57	Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 570-581.	2.5	64
58	Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 492-522.	2.5	200
59	Expression of the Tumor Suppressor Protein 14-3-3 β Is Down-regulated in Invasive Transitional Cell Carcinomas of the Urinary Bladder Undergoing Epithelial-to-Mesenchymal Transition. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 410-419.	2.5	70
60	Impact of proteomics on bladder cancer research. <i>Pharmacogenomics</i> , 2004, 5, 381-394.	0.6	37
61	Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 327-344.	2.5	278
62	Towards discovery-driven translational research in breast cancer. <i>FEBS Journal</i> , 2004, 272, 2-15.	2.2	45
63	Cell of the month: Transformed human epithelial cells. <i>Nature Cell Biology</i> , 2004, 6, 1163-1163.	4.6	0
64	Image competition. <i>Nature Reviews Molecular Cell Biology</i> , 2004, 5, 957-957.	16.1	0
65	The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. <i>BMC Cancer</i> , 2003, 3, 30.	1.1	128
66	Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research. <i>Molecular and Cellular Proteomics</i> , 2003, 2, 369-377.	2.5	44
67	Neither Reb1p nor Poly(dA-dT) Elements Are Responsible for the Highly Specific Chromatin Organization at the ILV1 Promoter. <i>Journal of Biological Chemistry</i> , 2002, 277, 3202-3209.	1.6	12
68	Chromatin-mediated transcriptional regulation by the yeast architectural factors NHP6A and NHP6B. <i>EMBO Journal</i> , 2000, 19, 6804-6813.	3.5	60
69	Nucleosome structure of the yeast CHA1 promoter: analysis of activation-dependent chromatin remodeling of an RNA-polymerase-II-transcribed gene in TBP and RNA pol II mutants defective in vivo in response to acidic activators. <i>EMBO Journal</i> , 1998, 17, 6028-6038.	3.5	71
70	Datin, a yeast poly(dA-dT)-binding protein, behaves as an activator of the wild-type ILV1 promoter and interacts synergistically with Reb1p. <i>Molecular Genetics and Genomics</i> , 1998, 258, 95-103.	2.4	12